MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Начало・Списък с акции・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

75.12 0.35

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

74.26

Максимум

76.3

Ключови измерители
By Trading Economics
Приходи	-100M -229M
Продажби	46M 203M
Марж на печалбата	-112.808
Служители	1,402
EBITDA	4.7B 4.6B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+29.43% upside

Дивиденти
By Dow Jones
Следващи печалби	29.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.7B 12B
Предишно отваряне	74.77
Предишно затваряне	75.12

Настроения в новините

By Acuity

50%

148 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

29.78 / 33.645 Подкрепа & съпротива

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.04.2026 г., 22:56 ч. UTC

Значими събития в новините

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1.04.2026 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1.04.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1.04.2026 г., 23:23 ч. UTC

Значими събития в новините

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1.04.2026 г., 23:07 ч. UTC

Печалби

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1.04.2026 г., 23:02 ч. UTC

Значими събития в новините

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1.04.2026 г., 22:39 ч. UTC

Печалби

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1.04.2026 г., 22:08 ч. UTC

Пазарно говорене

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1.04.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1.04.2026 г., 21:31 ч. UTC

Значими събития в новините

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.04.2026 г., 20:38 ч. UTC

Печалби

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1.04.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1.04.2026 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1.04.2026 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1.04.2026 г., 20:13 ч. UTC

Придобивния, сливания и поглъщания

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1.04.2026 г., 20:07 ч. UTC

Пазарно говорене

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1.04.2026 г., 20:07 ч. UTC

Придобивния, сливания и поглъщания

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

29.43% нагоре

12-месечна прогноза

Среден 97.19 USD 29.43%

Висок 120 USD

Нисък 72 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Ionis Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Настроение

By Acuity

148 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.